WO2023038600 - A CAPSULE FORMULATION COMPRISING MACITENTAN
National phase entry:
Publication Number
WO/2023/038600
Publication Date
16.03.2023
International Application No.
PCT/TR2022/050945
International Filing Date
05.09.2022
Title **
[English]
A CAPSULE FORMULATION COMPRISING MACITENTAN
[French]
FORMULATION DE CAPSULE COMPRENANT DU MACITENTAN
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
ARI, Busra
ERDOGAN, Akif
Priority Data
2021/013983
07.09.2021
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2100 | |
| EPO | Filing, Examination, Granting | 9157 | |
| Japan | Filing, Examination, Granting | 2153 | |
| South Korea | Filing, Examination, Granting | 2137 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,287
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a capsule formulation comprising macitentan free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters and at least one pharmaceutically acceptable excipient.[French]
La présente invention concerne une formulation de capsule comprenant une base libre de macitentan ou sous la forme de sels, de polymorphes cristallins, de solvates, d'hydrates, d'esters pharmaceutiquement acceptables, et au moins un excipient pharmaceutiquement acceptable.